Molecular Cancer 2

Comprehensive
Somatic Mutation Testing

  • Comprehensive Somatic Mutation Testing

    Somatic Mutation Brochure arrow icon   Somatic Mutation Request Form arrow icon

    Local and International Guidelines (NCCN & ASCO) strongly recommend comprehensive multi-gene panel– based genomic sequencing for cancer patients with the goal of identifying rare driver mutations for which effective drugs may already be available. Comprehensive tumour profiling aids clinicians in selecting the most appropriate treatment for their cancer patients, avoiding unnecessary toxic therapy, resistance, or overtreatment, or in suggesting potential synergistic drug combinations (e.g., combination of BRAF and MEK inhibitors in BRAF mutant melanoma)1. This approach is also of valuable use if the tumour his poorly differentiated or of unknown origin.

    Comprehensive Oncomine Precision Assay (OPA) Gene Panel (ThermoFisher Scientific)

    Genes sequenced in this panel include:

    Scroll indicator
    AKT1CHEK2FGFR3KITNTRK3
    AKT2CTNNB1FGFR4KRASPDGFRA
    AKT3EGFRFLT3MAP2K1PIK3CA
    ALKERBB2GNA11MAP2K2PTEN
    ARERBB3GNAQMETRAF1
    ARAFERBB4GNASMTORRET
    BRAFESR1HRASNRASROS1
    CDK4FGFR1IDH1NTRK1SMO
    CDKN2AFGFR2IDH2NTRK2TP53
    Scroll indicator

    How to Order Comprehensive Somatic Mutation Cancer Gene Panel

    When to Order:

    • Comprehensive Diagnostic Protocol for Solid Tissue Cancers.

    Request Form Instructions:

    • Fill out our Somatic Mutation testing request form and tick the Somatic Mutation test panels required.

    Specimen Details:

    • Fresh formalin-fixed paraffin-embedded (FFPE) of 5-10 μm thickness from the tumour tissue.

    Test Cost:

    • The Comprehensive Tumour Somatic Mutation Panel is Non-Medicare rebatable. An out-of-pocket fee of $750 applies.

    Turnaround Time:

    • 5-7 business days after the receipt of the sample.

References

  1. Malone E et al., Genome Medicine (2020). Molecular profiling for precision cancer therapies 12:8.

About the Author

Associate Professor Mirette Saad

Associate Professor Mirette Saad

MBBS(Hons) MD(Hons) MAACB FRCPA PhD

Associate Professor Mirette Saad

MBBS(Hons) MD(Hons) MAACB FRCPA PhD
Location: Clayton (VIC)
Speciality: Chemical Pathology
Areas of Interest:
  • antenatal screening
  • cancer genetics
  • clinical research and medical teaching
  • endocrine
  • fertility testing
  • molecular genetics
  • nipt
  • precision medicine
About

Associate Professor Mirette Saad is a Consultant Chemical Pathologist and the National Director of Molecular Genetics at Australian Clinical Labs. She has a Fellowship with honours in Chemical and Molecular Pathology, with Microbiology sub-speciality, from overseas. A/P Saad received her NHMRC sponsored PhD degree in Cancer Genetics from Melbourne University and Peter MacCallum Cancer Institute. Along with her teaching and research roles, A/P Saad is a registered medical practitioner with AHPRA, a Chemical Pathology Fellow (FRCPA) at the Royal College of Pathologists of Australasia and a Member of the Australasian Association of Clinical Biochemists (MAACB). She is a Chair of the RCPA Chemical Pathology Advisory Committee, Member of the RCPA Genetic Advisory Committee, AACB and a Chair of the Precision Medicine Services at Australian Clinical Labs. At Clinical Labs, A/Prof Mirette Saad leads the Molecular Genetic testing for NIPT, antenatal screening, personalised drug therapy and cancer.